Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Nuzzo F, Morabito A, Gravina A, Di Rella F, Landi G, Pacilio C, Labonia V, Rossi E, De Maio E, Piccirillo MC, D'Aiuto G, Thomas R, Rinaldo M, Botti G, Di Bonito M, Di Maio M, Gallo C, Perrone F, de Matteis A. Nuzzo F, et al. Among authors: di rella f, di maio m, di bonito m. BMC Cancer. 2011 Feb 16;11:75. doi: 10.1186/1471-2407-11-75. BMC Cancer. 2011. PMID: 21324184 Free PMC article. Clinical Trial.
Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G. Frasci G, et al. Among authors: di bonito m. Breast Cancer Res Treat. 1999 Aug;56(3):239-52. doi: 10.1023/a:1006263226099. Breast Cancer Res Treat. 1999. PMID: 10573115 Clinical Trial.
Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Di Bonito M, Rivellini F, Carteni G, De Lucia L, Maiorino L, D'Aniello R, Frezza P, Lapenta L, Comella G. Frasci G, et al. Among authors: di bonito m. Breast Cancer Res Treat. 2000 Jul;62(2):87-97. doi: 10.1023/a:1006429205363. Breast Cancer Res Treat. 2000. PMID: 11016746 Clinical Trial.
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G, Comella P, Thomas R, Di Bonito M, Lapenta L, Capasso I, Botti G, Vallone P, De Rosa V, D'Aiuto G, Comella G. Frasci G, et al. Among authors: di bonito m. Cancer Chemother Pharmacol. 2004 Jan;53(1):25-32. doi: 10.1007/s00280-003-0669-x. Epub 2003 Sep 26. Cancer Chemother Pharmacol. 2004. PMID: 14513281 Clinical Trial.
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G; Southern Italy Cooperative Oncology Group (SICOG). Frasci G, et al. Among authors: di bonito m. Br J Cancer. 2006 Oct 23;95(8):1005-12. doi: 10.1038/sj.bjc.6603395. Br J Cancer. 2006. PMID: 17047649 Free PMC article. Clinical Trial.
116 results